Therapy
152 tracked therapy entities, ordered by how much was published about each in the last 30 days. 278 papers across 109 of them.
- Doxorubicin 13 papers
- Metformin 9 papers
- Rituximab 8 papers
- Cisplatin 7 papers
- Pembrolizumab 7 papers
- Bevacizumab 6 papers
- Deep brain stimulation 6 papers
- Nivolumab 6 papers
- Checkpoint inhibitor 5 papers
- COVID-19 vaccine 5 papers
- Dexamethasone 5 papers
- Glucagon-like peptide-1 agonist 5 papers
- HPV vaccine 5 papers
- Immunotherapy 5 papers
- Neoadjuvant chemotherapy 5 papers
- Robot-assisted radical prostatectomy 5 papers
- Semaglutide 5 papers
- Adalimumab 4 papers
- Liver transplantation 4 papers
- Oxaliplatin 4 papers
- Tirzepatide 4 papers
- Cabotegravir 3 papers
- Dupilumab 3 papers
- Electroacupuncture 3 papers
- Gemcitabine 3 papers
- Immunization 3 papers
- Infliximab 3 papers
- Influenza vaccine 3 papers
- Melatonin 3 papers
- Osimertinib 3 papers
- Paclitaxel 3 papers
- PARP inhibitor 3 papers
- Photobiomodulation 3 papers
- Photothermal therapy 3 papers
- Proprotein convertase subtilisin/kexin type 9 inhibitors 3 papers
- Recombinant zoster vaccine 3 papers
- Rifampicin 3 papers
- Sorafenib 3 papers
- Tyrosine-kinase inhibitor 3 papers
- Allogeneic hematopoietic stem cell transplantation 2 papers
- Antibiotic 2 papers
- Antibody-drug conjugate 2 papers
- Aspirin 2 papers
- Botulinum toxin type A 2 papers
- Capecitabine 2 papers
- CAR-T cells 2 papers
- Carboplatin 2 papers
- Cognitive behavioral therapy 2 papers
- Cyclophosphamide 2 papers
- Dapagliflozin 2 papers
- Dasatinib 2 papers
- Fluorouracil 2 papers
- Glucocorticoid 2 papers
- HPV vaccination 2 papers
- Ibuprofen 2 papers
- Methotrexate 2 papers
- Monoclonal antibody 2 papers
- Olaparib 2 papers
- Propofol 2 papers
- Proton therapy 2 papers
- Radiation therapy 2 papers
- Resection 2 papers
- RNA vaccine 2 papers
- Stereotactic radiosurgery 2 papers
- Sunitinib 2 papers
- Tocilizumab 2 papers
- Trastuzumab 2 papers
- Upadacitinib 2 papers
- Ustekinumab 2 papers
- Venetoclax 2 papers
- (S)-(−)-colchicine 1 paper
- Abemaciclib 1 paper
- Adjuvant chemotherapy 1 paper
- Anti-PD-1 therapy 1 paper
- Anti-PD-L1 1 paper
- Antimicrobial 1 paper
- Atezolizumab 1 paper
- Belimumab 1 paper
- Celecoxib 1 paper
- Cetuximab 1 paper
- Docetaxel 1 paper
- Doxycycline 1 paper
- Enfortumab vedotin 1 paper
- Erlotinib 1 paper
- Finerenone 1 paper
- Gene therapy 1 paper
- Imatinib 1 paper
- Influenza vaccination 1 paper
- Janus kinase inhibitors 1 paper
- Lenvatinib 1 paper
- Levodopa 1 paper
- Mesalazine 1 paper
- Methylprednisolone 1 paper
- Nirsevimab 1 paper
- Ocrelizumab 1 paper
- Platelet-rich plasma 1 paper
- Pneumococcal conjugate vaccine 1 paper
- Prodrug 1 paper
- Propranolol 1 paper
- Proteolysis-targeting chimeras 1 paper
- Romosozumab 1 paper
- Simvastatin 1 paper
- Sirolimus 1 paper
- Small molecule inhibitors 1 paper
- Tacrolimus 1 paper
- Tislelizumab 1 paper
- Tofacitinib 1 paper
- Vancomycin 1 paper
- Vitamin D 1 paper
- Anchusin
- Atorvastatin
- Automated Insulin Delivery
- Bispecific antibodies
- Bortezomib
- Cabozantinib
- Caelyx
- Ceftazidime-avibactam
- Celastrol
- Chemoimmunotherapy
- Chemoradiotherapy
- Chimeric Antigen Receptor T-cell therapy
- Ciprofloxacin
- Cisplatin/fluorouracil
- Combination therapy
- Continuous positive airway pressure
- Cyclin-dependent kinase 4/6 inhibitors
- Daratumumab
- Direct oral anticoagulants
- Dolutegravir
- Durvalumab
- Empagliflozin
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
- Fenofibrate
- Histone deacetylase inhibitors
- Ibrutinib
- Insulin Therapy
- Ipilimumab
- Lenalidomide
- Liraglutide
- Meropenem
- Niraparib
- PD-1/PD-L1 blockade
- Platinum
- Resmetirom
- Rutin
- Ruxolitinib
- Sodium glucose cotransporter-2 (SGLT2) inhibitors
- Statin
- Tamoxifen
- Taxane
- Temozolomide
- Vorinostat